Nov 13, 2026 · CURE Today

WEARABLE DEVICE DELAYS PAIN IN PANCREATIC CANCER

A secondary analysis of the phase 3 PANOVA-3 trial, published November 13 in JAMA Network Open, found that people with locally advanced pancreatic cancer who wore the Optune Pax device with chemotherapy went about three months longer before their pain worsened than those on chemotherapy alone: 10.1 months versus 7.4 months for general pain, and 14.7 versus 10.2 months for pancreatic cancer-specific pain. The trial enrolled 571 people. For clinics that see cancer-related pain, the result adds to the evidence that non-drug pain control can meaningfully delay worsening pain, though the device is used alongside chemotherapy, not instead of it.

Pain Jobs — a job board for pain management professionals.

Jobs

All jobs

News

All news